Cargando…
Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD
Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β(2)-agonist (LABA) fixed dose combination (FDC) using a multidimen...
Autores principales: | Montuschi, Paolo, Santini, Giuseppe, Mores, Nadia, Vignoli, Alessia, Macagno, Francesco, Shoreh, Rugia, Tenori, Leonardo, Zini, Gina, Fuso, Leonello, Mondino, Chiara, Di Natale, Corrado, D'Amico, Arnaldo, Luchinat, Claudio, Barnes, Peter J., Higenbottam, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914154/ https://www.ncbi.nlm.nih.gov/pubmed/29719507 http://dx.doi.org/10.3389/fphar.2018.00258 |
Ejemplares similares
-
New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine
por: Paggiaro, Pierluigi
Publicado: (2009) -
Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations
por: Nicolini, Gabriele, et al.
Publicado: (2008) -
Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014) -
Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients
por: Tzani, Panagiota, et al.
Publicado: (2011) -
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018)